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Abstract
Usher 1 patients are born profoundly deaf and then develop retinal degeneration. Thus they are 
readily identified prior to the onset of retinal degeneration, making gene therapy a viable strategy 
to prevent their blindness. Here, we have investigated the use of adeno-associated viruses (AAV) 
for the delivery of the Usher 1B gene, MYO7A, to retinal cells in cell culture and in Myo7a-null 
mice. MYO7A cDNA, under control of a smCBA promoter, was packaged in single AAV2 and 
AAV5 vectors, and as two overlapping halves in dual AAV2 vectors. The 7.9-kb smCBA-MYO7A 
exceeds the capacity of an AAV vector; packaging of such oversized constructs into single AAV 
vectors may involve fragmentation of the gene. Nevertheless, the AAV2 and AAV5 single vector 
preparations successfully transduced photoreceptor and RPE cells, resulting in functional, full-
length MYO7A protein and correction of mutant phenotypes, suggesting successful homologous 
recombination of gene fragments. With discrete, conventional-sized dual AAV2 vectors, full-
length MYO7A was detected, but the level of protein expression was variable, and only a minority 
of cells showed phenotype correction. Our results show that MYO7A therapy with AAV2 or 
AAV5 single vectors is efficacious, however, the dual AAV2 approach proved to be less effective.
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Introduction
Many inherited retinal diseases are caused by loss of function of a single gene that is 
expressed in the photoreceptor cells and/or the retinal pigment epithelium (RPE), with 
progressive retinal degeneration resulting in blindness. These diseases should therefore be 
preventable by the introduction of a wildtype version of the mutant gene into the 
photoreceptor and/or RPE cells, prior to the onset of retinal degeneration. Proof of this 
principle has now been demonstrated in clinical trials with patients possessing Leber 
congenital amaurosis, due to loss of function of the RPE65 gene 1-4.
In Usher syndrome, retinal degeneration occurs in conjunction with deafness. In most cases, 
the deafness is congenital; in Usher syndrome type 1, patients are born profoundly deaf. 
These patients are thus readily identified when infants, prior to the onset of retinal 
degeneration, making gene therapy a viable strategy to prevent their blindness.
The most common form of Usher syndrome type 1 is Usher 1B, which accounts for at least 
half of Usher 1 cases. It is caused by mutations in the MYO7A gene 5. Together with light 
chains, MYO7A forms the actin-based motor, myosin 7a. Myosin 7a has a variety of 
functions in the photoreceptor and RPE cells 6-11. The recessive inheritance of Usher 
syndrome, together with MYO7A disease alleles that are likely null, indicate that Usher 1B is 
primarily due to loss of MYO7A function e.g. 12, so that the progressive blindness should 
therefore be preventable by delivering a wildtype gene to the photoreceptor and RPE cells 
prior to any cell degeneration. A limitation is that MYO7A is a large gene; its cDNA is 
nearly 7 kb 13, 14. This large size is particularly a concern for using adeno-associated virus 
(AAV) to deliver the gene. AAV has been used successfully in clinical and preclinical 
retinal gene therapy experiments 1-4, 15, but its nominal packaging size was reported to be 
~5.3 kb 16. Because of the size of MYO7A, we initially studied the use of a lentiviral vector 
to deliver MYO7A cDNA to the RPE and photoreceptor cells 17. Following subretinal 
injection of mice, we observed correction of mutant phenotypes in the RPE and 
photoreceptor cells. However, the integrating nature of lentiviral vectors poses a concern 
with respect to the introduction of insertional mutagenesis, as well as different responses 
among different cells due to cell to cell variation in the integration of the gene. By contrast, 
AAV transduction results in mostly episomal DNA, which has been shown to be stable in 
terminally-differentiated cells, such as photoreceptor and RPE cells 18, 19.
More recently, we showed that AAV5 was able to mediate expression of full length 
MYO7A protein in RPE cells in primary culture 20. Subsequent studies by three independent 
groups found that AAV could deliver other large genes, although they showed that the DNA 
was first fragmented into sizes consistent with canonical AAV packaging (i.e. less than 5 
kb), and then the fragmented genes reassemble after delivery to the cell, presumably by 
recombination, to yield a full length cDNA 21-23. The ability of different cells to reassemble 
a given gene is likely to vary. In the present study, we have tested the ability of AAV-
MYO7A to transduce RPE and photoreceptor cells in vivo, and to correct mutant phenotypes 
in mice that are null for the Usher 1B orthologue, Myo7a. We demonstrate efficacy not only 
with AAV5, but also the more commonly used serotype, AAV2.
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Due to the possible heterogeneous nature of genes delivered by these single AAV vectors, 
we also tested a dual vector preparation, with two AAV2 vectors, each containing an 
overlapping half of MYO7A. Comparable dual vector systems have been tested previously, 
showing some modest success as gene therapy vectors in animal models of Duchenne’s 
muscular dystrophy 24, 25, but, to date, no such approach has been used to address retinal 
disease associated with a large gene. Our results indicate that this dual vector approach is 
significantly less effective than using the single AAV2 or AAV5 vectors to deliver 
functional MYO7A to the photoreceptor and RPE cells.
RESULTS
AAV-MYO7A single vector preparations
AAV vector plasmid was engineered to contain a truncated chimeric CMV/chicken β-actin 
promoter, smCBA 26 and the 6.7-kb cDNA encoding the full length isoform 2 of human 
MYO7A (Fig. 1a). The smCBA promoter exhibits the same tropism and activity in mouse 
retinas as that of the full-length CBA promoter 26, 27. Titers of 1012 to 1013 particles/mL 
were obtained for different lots of AAV2-MYO7A and AAV5-MYO7A. A concentration of 
1012 particles/mL was regarded as our standard concentration (1x), from which dilutions 
were made. The experiments were performed with virus obtained from three separate 
preparations. No differences in expression or phenotype correction, as described below, 
were observed among the different lots for AAV2-MYO7A or AAV5-MYO7A at a given 
concentration.
MYO7A expression in cell culture
Transduction of primary cultures of Myo7a-null RPE cells with 1x single AAV2-MYO7A or 
AAV5-MYO7A resulted in the expression of a polypeptide that, by western blot analysis, 
had an apparent mass that was comparable to that of WT MYO7A protein, and was present 
at similar levels to that found in primary cultures of Myo7a+/−RPE cells (Fig. 1b). Likewise, 
a single band of appropriate size was detected on western blots of HEK293A cells (data not 
shown). Immunofluorescence of the primary RPE cells showed that the MYO7A protein, 
resulting from 1x single AAV-MYO7A treatment of MYO7A-null cells, had a subcellular 
localization pattern that was comparable to that of endogenous MYO7A in control cells, 
indicating the generation of appropriately targeted protein (Fig. 1c-f). ARPE19 cells were 
also infected with 1x or diluted (1:100) AAV2-MYO7A or AAV5-MYO7A, and compared 
with non-treated cells. An increase in MYO7A immunofluorescence was detected in the 
treated cells, and the intracellular localization of the label was comparable to that in 
untreated cells (Suppl. Fig. 1a-e).
Localization of MYO7A in vivo
Most retinal MYO7A is found in the RPE 28, however, the protein is also present in the 
connecting cilium and pericilium of the photoreceptor cells 29, 30. A diagram illustrating this 
distribution and the retinal functions of MYO7A has been published in a recent review 11.
Three weeks following injection of 1x AAV2-MYO7A or AAV5-MYO7A into the subretinal 
space of Myo7a-null mice, retinal tissue was examined by immunoelectron microscopy to 
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test for MYO7A expression. Near the site of injection (within 1.4 mm), immunogold label 
was evident in the photoreceptor cells, where it was localized in the connecting cilium and 
pericilium, comparable to that in WT retinas (Fig. 2a-e). Label was also present throughout 
the RPE cells, particularly in the apical cell body region (Fig. 2f-g), as found in WT 
retinas 9, 29. At the periphery of the retina, no significant immunolabel was detected (Suppl. 
Fig. 2).
MYO7A has a similar distribution in both rod and cone photoreceptor cells 7. To test 
whether treatment with AAV-MYO7A also affected cone photoreceptor cells, we determined 
whether MYO7A was also present in the ciliary region of cone photoreceptors. We 
performed double immunoEM of treated retinas, using a MYO7A antibody together with an 
antibody specific for rod opsin. Although there are only a small number of cones with 
aligned connecting cilia found in each ultrathin section, MYO7A immunogold label was 
evident in the connecting cilium and periciliary region of these cones, which were identified 
by lack of rod opsin labeling in their outer segments (in contrast to the surrounding rod outer 
segments) (Fig. 2h, i). Hence, AAV2-MYO7A and AAV5-MYO7A can transduce cone as 
well as rod photoreceptor cells.
Dose-dependent MYO7A expression in photoreceptor and RPE cells
To determine the levels of MYO7A expression following treatment with different 
concentrations of AAV2-MYO7A and AAV5-MYO7A (1x, 1:10 or 1:100 dilutions), we 
quantified MYO7A immunogold labeling in EM images, taken within 1.4 mm of the 
injection site. Reliable detection of MYO7A in the photoreceptor cells, where its distribution 
is limited to the connecting cilium and pericilium, requires the higher resolution provided by 
electron microscopy 29. Immunogold particle density was measured in images of the 
photoreceptor connecting cilium and pericilium, shown in complete longitudinal section 
(from the basal bodies to the base of the outer segment), and in images showing the RPE 
cells in apical to basal section. Particle density was expressed as particles per length of 
cilium for the photoreceptor cells (each connecting cilium is ~1.2 um long), and as particles 
per area for the RPE cells (the entire area between the apical and basal surfaces was 
included). Particle density is dependent on exposure of epitopes on the surface of the 
section, and, as such, provides a relative linear measure of antigen density under the 
conditions used here (i.e. grids were etched and labeled in an identical manner, and the 
labeling was not so dense as to be affected by steric hindrance).
Treatment with 1x AAV2-MYO7A or AAV5-MYO7A resulted in 2.5-2.7 times the density of 
immunolabel in the photoreceptor cilium, compared with that found in WT retinas, while the 
1:10 and 1:100 dilutions resulted in a density of immunolabel that was more comparable to 
WT levels (Fig. 2j and l; Suppl. Fig. 3). Quantification of immunogold label in the RPE 
showed that injection of AAV2-MYO7A resulted in 2.7 times more label than in WT, with 
the 1:10 and 1:100 dilutions showing no significant difference (Fig. 2k). In contrast, the 
level of MYO7A immunolabel in the RPE of retinas injected with AAV5-MYO7A varied in 
relation to virus titer, with the full dose virus effecting 2.2-fold more MYO7A than that 
found in WT RPE, the 1:10 dilution effecting WT levels, and the 1:100 dilution resulting, on 
average, ~60% of WT levels (Fig. 2m).
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These counts of labeling density indicate that 1x AAV-MYO7A resulted in more than double 
the normal level of MYO7A expression in both the photoreceptor and RPE cells. The 
distribution of MYO7A was not affected by this overexpression in the photoreceptor cells. 
In the RPE cells, the overall distribution of MYO7A was comparable to WT, with a higher 
concentration in the apical cell body region. However, with 1x AAV2-MYO7A or 1x AAV5-
MYO7A, the proportion of MYO7A that was associated with melanosomes was only just 
over half that in WT RPE: in WT RPE, we found that 42% of the MYO7A immunogold 
particles were located near the membrane of melanosomes; in retinas treated with 1X 
AAV2-MYO7A, we found 23%; and in retinas treated with 1X AAV2-MYO7A, we found 
24%. This difference is possibly because the proteins that link MYO7A to the melanosomes, 
MYRIP and RAB27A 31, 32, may have remained near WT levels, and thus limited the 
absolute amount of MYO7A that could associate with the melanosomes.
Despite the overexpression of MYO7A, no pathology was evident in retinas, up to 3 months 
after injection of 1x (or 1:10) AAV2-MYO7A. However, two out of six retinas injected with 
1013 particles/mL of AAV5-MYO7A (i.e. 10x) showed evidence of photoreceptor cell loss 
across the retina after 3 weeks (AAV2-MYO7A was not tested at this titer) (Suppl. Fig. 4).
Correction of melanosome localization in the RPE
In Myo7a-mutant mice, melanosomes are absent from the apical processes of the RPE 
cells 6. This mutant phenotype is evident at all neonatal ages, and is due to loss of actin-
based transport of the melanosomes by the myosin 7a motor 9. Three weeks following 
injection of 1x AAV2-MYO7A or AAV5-MYO7A into the subretinal space of Myo7a-null 
mice, melanosomes were observed to have a normal distribution in all RPE cells near the 
site of injection (within 1.4 mm) (n=10 each for AAV2-MYO7A and AAV5-MYO7A) (Fig. 
3a-c). Well away from the injection site, a mixture of corrected and uncorrected RPE cells 
was evident, while, at the periphery of the retina, the cells all exhibited the Myo7a-mutant 
phenotype, indicating lack of correction in this region (Fig. 3d-f). The correction of 
melanosomes was still evident in retinas that were fixed 3 months after injection (Suppl. Fig. 
5). Correction was also observed in all eyes injected with 1:10 dilution AAV2-MYO7A 
(n=6) or AAV5-MYO7A(n=6), as well as in all eyes injected with 1:100 dilution AAV2-
MYO7A (n=6) or AAV5-MYO7A (n=6), although with the 1:100 dilution some of the RPE 
cells near the site of injection were not corrected.
Correction of opsin distribution
Myo7a-mutant mice have an abnormal accumulation of opsin in the connecting cilia of the 
photoreceptor cells, a phenotype that is evident by immunoEM with opsin antibodies 7. This 
mutant phenotype suggest that myosin 7a functions in the vectorial delivery of opsin to the 
outer segment 7. Quantification of immunogold opsin labeling in the connecting cilia, 
demonstrated that this phenotype was corrected with 1x AAV2-MYO7A or AAV5-MYO7A 
(Fig. 3g; Suppl. Fig. 6). This analysis also showed phenotype correction with 1:100 
dilutions, although the data indicated that a full WT phenotype was not achieved (Fig. 3g), 
despite WT levels of MYO7A (Fig. 2j, l), suggesting that some of the MYO7A may not be 
fully functional.
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AAV2-MYO7A dual vector preparations
The preceding results demonstrate that a single AAV vector is capable of delivering 
functional MYO7A to the RPE and photoreceptor cells in vivo. Because the size of smCBA-
MYO7A is ~2 kb larger than the nominal carrying capacity of an AAV 16, this transduction 
might involve undefined fragmentation of the smCBA-MYO7A cDNA, followed by 
reassembly of plus and minus cDNA strands after delivery to the cell, as shown for other 
large genes 21-23. To evaluate whether two AAV vectors containing defined, overlapping 
fragments of MYO7A cDNA (1365 bases) were also capable of mediating full length 
MYO7A expression, we developed an AAV2-based dual vector system (Fig. 4a). Two 
separate lots of the AAV2-MYO7A(dual vector) were prepared, each containing equal 
concentrations of AAV2-smCBA-MYO7A(5′-half) and AAV2-MYO7A(3′-half). The titer of 
the first lot contained 2.5 × 1012 particles/mL of each vector, and the second lot contained 4 
× 1012 particles/mL.
MYO7A expression with AAV2 dual vectors
Western blot analysis of primary cultures of Myo7a-null RPE cells, infected with AAV2-
MYO7A(dual vector) of either lot, showed that the cells expressed a MYO7A-
immunolabeled polypeptide of comparable mass to that of WT MYO7A (Fig. 4b). However, 
the overall expression level of MYO7A in the treated Myo7a-null RPE cells was 
significantly less than that found in primary cultures of Myo7a+/− RPE cells (Fig. 4b), and 
significantly less than that expressed after infection by the single AAV2 or AAV5 vectors 
(Fig. 4c). Quantitative analysis of western blots showed that Myo7a-null RPE cells, 
transduced with the single vectors (1x), AAV2-MYO7A or AAV5-MYO7A, or with AAV2-
MYO7A(dual vector), expressed MYO7A at levels that were 82%, 111%, and 10%, 
respectively, of the level of MYO7A in Myo7a+/− RPE cells.
Immunofluorescence of primary Myo7a-null RPE cells, infected with AAV2-MYO7A(dual 
vector), showed that a few cells scattered throughout the culture exhibited very high levels 
of MYO7A, but all other cells contained insignificant levels (Fig. 4d-f). The cells 
overexpressing MYO7A typically had altered morphology, suggesting that the high levels of 
MYO7A may be toxic. Similarly, immunofluorescence of ARPE19 cells, infected with 
AAV2-MYO7A(dual vector), resulted in a minority of cells that were labeled intensely with 
MYO7A antibody, with most of the cells appearing to express only endogenous levels of 
MYO7A (Fig. 4g; Suppl. Fig. 1f).
Immunolabeling of retinas, prepared 3 weeks after subretinal injection with AAV2-
MYO7A(dual vector) of either lot, also showed only a few RPE cells and photoreceptor cells 
with clear MYO7A expression, although significant overexpression was not evident in this 
in vivo experiment. Immunogold particle counts from images of ultrathin sections were used 
to quantify the level of MYO7A expression in Myo7a-null retinas that were treated with the 
second lot of AAV2-MYO7A(dual vector). Within 1.4 mm of the injection site, MYO7A 
immunolabeling of the connecting cilium and pericilium of the photoreceptor cells was a 
mean of 48% of that in WT retinas: 2.8 particles/μm (n=3 retinas) compared with 6.5 
particles/μm for WT (n=3 retinas). The mean label density in apical-basal sections of the 
RPE was 35% of that in WT retinas: 11 particles/100 μm2 compared with 31 particles/100 
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μm2 for WT. However, it was clear that these lower means were achieved by some cells 
expressing near normal amounts of MYO7A and the majority expressing very little; over 
half the cells had fewer than 10 particles/100 μm2 (Fig. 4h).
Correction of Myo7a-mutant phenotypes with AAV2 dual vectors
Eyes were analyzed for correction of melanosome localization and ciliary opsin distribution 
within 1.4 mm of the injection site. With either lot of AAV2-MYO7A(dual vector), some 
RPE cells (29% for lot 1 treatment (n=6 retinas), 35% for lot 2 treatment (n=9 retinas)) were 
observed to have a normal apical melanosome distribution, but most of the cells in this 
region retained the Myo7a-mutant phenotype, resulting in a mosaic effect (Fig. 5a) that 
contained a much lower proportion of corrected cells than that observed with a 1:100 
dilution of either of the single vectors. The only correction observed in 3 eyes injected with 
a 1:10 dilution of AAV2-MYO7A(dual vector) (first lot), was in 18% of the RPE cells in one 
of the retinas. With full-strength of AAV2-MYO7A(dual vector) (second lot), opsin 
immunogold density averaged 3.2 + 0.4 particles/μm of cilium length, which was reduced 
from untreated retinas (4.2 + 0.8 particles/μm; p=0.003), but still greater than WT levels (1.1 
+ 0.2 particles/μm), suggesting that most cells were not corrected. An example of a corrected 
cell is shown in Fig. 5g.
Using immunoelectron microscopy, we tested for a correlation between phenotype 
correction and the expression level of MYO7A, determined by the mean concentration of 
immunogold particles in an apical-basal section of each RPE cell (Fig. 5b-e). From the eyes 
injected with AAV2-MYO7A(dual vector) (second lot), we found that the corrected RPE 
cells contained a mean of 108% of the WT level of MYO7A (the minimum level was 82%). 
RPE cells that were not corrected contained a mean of 26% of the WT level of MYO7A (the 
maximum level was 92%). While these data show that higher expression of MYO7A is 
correlated with phenotype correction (Fig. 5f), it also indicates that some of the labeled 
MYO7A protein is not functional, given that melanosomes are localized normally in mice 
that are heterozygous for the Myo7a-null allele and have only ~50% of the WT level of 
MYO7A.
DISCUSSION
The efficacy of AAV2- and AAV5-mediated MYO7A delivery to the retinas of Myo7a-
mutant mice was tested in a preclinical study aimed at developing a treatment for preventing 
blindness in Usher 1B. Despite the large size of smCBA-MYO7A relative to the carrying 
capacity of AAV, single vector preparations of either serotype effected MYO7A expression 
in RPE and photoreceptor cells and corrected the mutant phenotypes in both cell types. In a 
different approach, using two discrete AAV2 vectors, each containing a different half of 
MYO7A cDNA, with a central overlapping region, MYO7A expression was detected, but 
only in a minority of cells, both in culture and in vivo. Likewise, the correction of mutant 
phenotypes was sporadic. These findings demonstrate the therapeutic potential of using a 
single AAV vector to deliver MYO7A, but they indicate limitations with an overlapping dual 
AAV vector approach.
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MYO7A delivery by AAV2 and AAV5 single vectors
Demonstration that AAV vectors mediate safe and effective therapy in clinical trials 1-4, 15 
has been limited to the delivery of small genes or reduced versions of larger ones. 
Recombinant DNA can only be efficiently packaged into AAV if the total DNA is less than 
about 5.3 kb. Capsids containing DNA larger than 5.3 kb exhibit a progressively reduced 
transduction efficiency until reaching the physical encapsidation limit of ~6 KB 16. The 
strategy of creating “mini” proteins, reduced to minimally essential domains, has been used 
in an attempt to make gene therapy with AAV tractable for large genes, such as 
dystrophin 33, although, limitations of this approach have been reported recently 15, 25. 
However, the mini gene approach is of little use for large molecular motor genes, such as 
MYO7A. MYO7A is composed of essential motor, neck and tail domains, which provide the 
mechanoenzymatic properties, a lever for the step-wise motion, and cargo binding sites, 
respectively. The essential nature of each domain is clear from structure-function studies of 
myosins 34-36. Moreover, MYO7A mutations throughout the gene have been shown to cause 
Usher 1B, demonstrating that a perturbation of any major domain is pathogenic e.g. 12 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MYO7A).
Previously, we showed that a single AAV5 vector was able to deliver MYO7A and ABCA4 
(8.9 kb) cDNA, resulting in full-length protein expression in cell culture 20. In vivo studies 
with Abca4-mutant mice indicated ABCA4 expression and a reduction in the abnormally-
high levels of lipofuscin in the RPE that results from ABCA4 dysfunction. More recently, it 
has been shown that full-length, large gene reconstruction results from recombination 
between fragmented plus and minus cDNA strands packaged into separate capsids 21-23. 
Using single-molecule sequencing, Kapranov et al. found that the accommodation of large 
genomes by AAV involves encapsidation of only the 3′ ITR and cleavage at the 5′ end, 
resulting in a heterogeneous population of fragmented genomes 37. These fragments thus 
require a recombination event between appropriate overlapping genome fragments to 
reconstitute a full-length cDNA in cells containing multiple viral copies.
Our results show that transduction of photoreceptor and RPE cells with either the AAV2 or 
AAV5 single vectors results in the expression of MYO7A of the correct molecular mass. If 
fragmentation of the gene is occuring during packaging into the vectors, these results 
indicate that the fragments recombine successfully within the target cells. The extent of 
recombination may be dependent on the recombinogenic nature of the transgene itself; 
MYO7A, in the present study, seems to recombine well from the fragments, whereas 
dystrophin, for example, recombines relatively poorly 22.
The level of expression of MYO7A observed in vivo was related to the titer of the vector 
delivered, with the exception of MYO7A levels in the RPE following treatment with AAV2-
MYO7A; these levels were similar across a 100-fold dilution range. Even with this 
exception, the relative expression between the photoreceptor and RPE cells did not vary 
substantially from the ratio found in WT retinas, despite the use of a non-native promoter in 
the vector, the large difference in MYO7A levels between the photoreceptor and RPE cells, 
and the use of two different AAV serotypes.
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Overexpression of MYO7A has been shown to be toxic in a previous study, using lentiviral 
delivery of MYO7A under a full CMV promoter 17, and, in the present study, we observed 
extensive photoreceptor cell death, following subretinal injection of 1013 vector genome 
containing particles/mL of AAV5-MYO7A (i.e. 10x). Nevertheless, the present results 
indicate that there is a fairly large tolerance for excessive MYO7A levels. Phenotype 
correction with no indication of deleterious effects was observed over a wide range of vector 
titers (1010 to 1012 particles/mL), resulting in a wide range of MYO7A levels, up to nearly 3 
times that found in the photoreceptor and RPE cells of WT retinas. Some overexpression 
may to be necessary in the photoreceptor cells, where some of the MYO7A was suggested to 
be not fully functional, based on counts of MYO7A and opsin immunogold particles, and 
the degree of correction of the opsin distribution.
MYO7A delivery by AAV2 dual vector
We also investigated whether a dual vector system composed of two vectors containing 
specfic overlapping MYO7A cDNA fragments would also promote therapy. AAV2 dual 
vectors were packaged so that each contained a 3′ or 5′ segment of the cDNA that was less 
than 5 kb, and each part shared an overlapping region of 1365 bases. Western blot analysis 
showed that infected cells were able to generate full length MYO7A from the two parts, 
however, immunolabeling of cells in vitro and in vivo showed that the majority of cells 
failed to make significant amounts of the protein. Moreover, the RPE cells in culture that did 
contain MYO7A expressed it at excessive levels, and our data correlating MYO7A 
immunolabeling with phenotype correction in the RPE suggested that some of the MYO7A 
that was produced in vivo was not functional. Further studies are needed to investigate the 
nature of this non-functional protein, as well as that which may have been generated by the 
photoreceptors following infection with single vector AAV-MYO7A.
The failure of the majority of the cells to express any detectable MYO7A seems to be 
independent of the efficiency of vector delivery to the target cells. The titers of the dual 
AAV2 vectors were slightly higher than the 1x titer used for the single AAV2 vector, yet the 
single vector was efficacious, resulting in WT levels of MYO7A, even at a 1:100 dilution. 
The probability of the two halves of MYO7A cDNA recombining therefore appears to be 
very low in most of the RPE and photoreceptor cells.
Can the dual vector design be improved so that it could be used for Usher 1B retinal gene 
therapy? Different overlapping regions of the gene may offer more reliable homologous 
recombination, although the choice of regions is quite limited for MYO7A, since neither half 
can be made much larger without exceeding the vector packaging limit. Previous studies 
have compared transduction with a single vector and dual overlapping vectors, and showed 
that transduction is typically less efficient with the dual vector, although they have only 
tested genes that are less than 5 kb 38, 39. An alternative is to use dual vectors in which the 
two segments of the cDNA are designed to trans-splice together. An earlier report showed 
an order of magnitude improvement with this design compared with homologous 
recombination via a simple overlapping region, although it still fell short of transduction 
with a single vector 40. Combining trans-splicing with recombination of an overlapping 
region has yielded more promising results 41, and could be applied to MYO7A. However, 
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when such hybrid (transplicing + overlapping) vectors were directly compared to an 
overlapping only dual vector system in-vivo, the overlapping vector proved to be most 
efficient 25.
An alternative approach for increasing the efficiency of a dual vector system may be the use 
of a different AAV serotype. The decision to test AAV2 in the present study was based on 
the current clinical use of this serotype 1-4, 15. Other serotypes, such as AAV5 and AAV8, 
have been reported to transduce photoreceptor and RPE cells with greater efficiency 42, 43, 
although, in the present study, the AAV5-MYO7A single vector was not found to transduce 
these cells with any greater efficiency than the AAV2-MYO7A single vector (Fig. 2). AAV 
vectors containing single or multiple tyrosine to phenylalanine (Y-F) mutations on their 
capsid surface have been found to increase transduction efficiency and expression kinetics 
relative to unmodified vectors, possibly due to the ability of the virus to avoid proteosomal 
degradation 44. The increased capacity of an AAV8(Y-F) mutant to restore function and 
preserve structure has been shown in two other mouse models of retinal disease 45, 46. 
However, in the case of MYO7A therapy, a concern is that approaches that increase the 
general level of expression of MYO7A protein might also to result in pathology of the 
higher expressing cells, as already indicated by the cultured RPE cells that were treated with 
the dual vector in the present study.
Potential treatment for Usher 1B
The mouse model we have used in the present study contains a null mutation for Myo7a
7, 47
. Like other Myo7a-mutant mice, and indeed most other Usher 1 mouse models, their 
retinas do not degenerate 30, 47. Nevertheless, the mouse represents a useful model for 
testing the efficacy of retinal gene therapy for Usher 1B. First, MYO7A has been 
demonstrated to function in the motility of melanosomes of human RPE cells, as it does in 
mouse RPE cells 48. Second, although null MYO7A alleles seem to have less severe retinal 
disease among Usher 1B patients, the primary effect of MYO7A mutations is loss of function 
of the mechanoenzyme 12. Therefore, testing the correction of mutant phenotypes in a 
Myo7a-null mouse, as an indicator of appropriate expression of functional MYO7A in the 
retina, is a valid preclinical approach for identifying a treatment to prevent blindness in 
Ush1B patients.
In the present study, we have shown that single AAV2 or AAV5 vector delivery of MYO7A 
to the photoreceptor and RPE cells provides effective therapy. Although this approach likely 
includes the production of random fragments of MYO7A, these fragments successfully 
recombined to express functional MYO7A, resulting in correction of mutant phenotypes. In 
contrast, recombination of two defined overlapping fragments of MYO7A, delivered by dual 
AAV2 vectors, was found to be inconsistent, with only sporadic phenotype correction 
observed.
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Materials and Methods
Animals
Shaker1 mice carrying the 4626SB allele, an effective null mutation 7, 47, were used on the 
C57BL6 genetic background, and maintained and genotyped as described 7, 8. They were 
maintained on a 12-hr light/12-hr dark cycle, with exposure to 10-50 lux of fluorescent 
lighting during the light phase, and were treated according to NIH and UCLA animal care 
guidelines. Homozygous mutants were distinguished from the heterozygous controls by their 
hyperactivity, head-tossing and circling behavior 49, and/or by a PCR/restriction digest 
assay.
Construction of AAV Vectors
Single vector platform: AAV vector plasmid, containing the truncated chimeric CMV/
chicken β-actin promoter (smCBA) 26 and MYO7A cDNA, was constructed by removing the 
full MYO7A cDNA from pEGFP-C2 by EagI and Sal I digest and ligating into pTR-smCBA-
GFP digested with Not I and Sal I (to remove GFP). The MYO7A cDNA (6.7 kb) 
corresponds to isoform 2 of human MYO7A, and was the same as that used previously 17, 
which was based on the sequence published by Chen et al. 13. MYO7A isoform 2 is 114-kb 
shorter than isoform 1 13, 14. The MYO7A cDNA and resulting junctions were fully 
sequenced prior to packaging. Vector plasmid was packaged and titered in AAV2 and 
AAV5 according to previously published methods 50, 51. Titers of 1012 to 1013 particles/mL 
were obtained for different batches of AAV2-MYO7A and AAV5-MYO7A.
Dual vector platform: Two separate vector plasmids were constructed. Vector A contains the 
strong, ubiquitous “smCBA” promoter and MYO7A cDNA encoding the N-terminal portion. 
Vector B contains MYO7A cDNA encoding the C-terminal portion and a poly-A signal 
sequence. Each vector plasmid contains both inverted terminal repeats (ITRs). Using PCR 
with full length cDNA of MYO7A isoform 2 (NCBI # NM_001127180) as template, the 
MYO7A cDNA was divided roughly in half with amplicons encompassing nucleotide 
positions 1 through 3644 (Vector A) and 2279 through 6647 (Vector B) relative to ATG 
start position 1 . The resulting two vector plasmids share 1365 bp of overlapping MYO7A 
sequence and are 5.0 and 4.9 KB in length, respectively, well within the size limitation of a 
standard AAV vector. Both vector plasmids were sequence verified and separately packaged 
by standard AAV production methods 50, 51. The titer of the first lot contained 2.5 × 1012 
particles/mL of each vector, and the second lot contained 4 × 1012particles/mL of each 
vector.
Viral delivery in vitro
HEK293A cells (Invitrogen, CA, USA), grown in DMEM with 10% FBS and 1x NEAA and 
Pen/Strep (Invitrogen, CA, USA) were plated in 6 well-plates. The next day cells were 
incubated, at 37 °C and 5% CO2, with AAV2- and AAV5-MYO7A at an MOI of 10,000 
viral particles/cell in 500 μl of complete medium, containing also 40 μM of calpain inhibitor 
(Roche). Two hours later complete medium was added. The next day the medium was 
changed, and cells were incubated for an additional 48 hrs. Alternatively, some cells were 
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transfected with 1 μg of vector pTR-smCBA-MYO7A, complexed with Lipofectamine 2000 
(ratio 1:3), according to the manufacturer’s instructions (Invitrogen, CA, USA).
Primary mouse RPE cells were derived from P14-P16 Myo7a-null animals and cultured in 
24-well dishes, as described 8, 52. After 48 hrs in culture, cells were transduced with viruses. 
Cells were incubated in 100 μl of complete medium, containing 40 μM of calpain inhibitor 
and 10,000 viral particles/cell from the full-strength AAV stocks. After 2 hours, 400 μl of 
complete medium was added to each well, and incubated overnight. The medium was 
changed the following day, and cells were incubated for an additional 48 hrs.
ARPE19 cells (ATCC) were cultivated in DMEM/F-12 with 10% FBS and split into 24-well 
plates with glass coverslips. Cells were grown to confluency and then transduced in the 
same way as were the primary RPE cells.
MYO7A expression analysis by Western blot and Immunofluorescence
HEK293A and primary mouse RPE cells that were tranduced with AAV-MYO7A were 
collected 3 days post-transduction. For western blot analyses, cells were collected and lysed 
in 20 mM TRIS, pH 7.4, 5 mM MgCl2, 10 mM NaCl, 1 mM DTT and 1x protease inhibitor 
cocktail (Sigma, MO, USA). Equivalent amounts of total protein were separated on a 7.5 % 
SDS-PAGE gel. After transfer, blots were blocked with 5% non-fat milk, and probed with 
mouse anti-MYO7A antibody, generated against residues 927-1203 of human MYO7A 
(Developmental Studies Hybridoma Bank, Iowa, USA) 53, and mouse anti-actin antibody 
(Sigma, MO, USA) as a loading control.
Immunofluorescence was performed with ARPE19 and mouse RPE primary cells, 3 days 
after infection. Cells were fixed in 4% formaldehyde, blocked with blocking solution (0.5% 
BSA/0.05% saponin in PBS), incubated with the mouse anti-MYO7A followed by goat anti-
mouse Alexa-568 (Molecular Probes, Invitrogen, USA). Coverslips were mounted with 
mounting medium containing DAPI (Fluorogel II, Electron Microscopy Sciences, USA) and 
visualised on a Leica confocal system.
Viral Delivery in vivo
Mice were anesthetized with 2.0-3.0% isoflurane inhalation. The pupils of the animals were 
dilated with 1% (w/v) atropine sulfate and 2.5% phenylephrine. A local anaesthetic, 0.5% 
proparacaine hydrochloride, was also administered. A sclerotomy in the temporal limbus 
was performed with a 27G needle. A 32 gauge blunt needle, attached to a microsyringe 
pump (WPI, USA), was inserted and 1 μl of viral solution was injected into the ventral 
subretinal space of P14-P16 animals. Retinal detachment was visualised under a dissecting 
microscope, and registered as indication of a positive subretinal injection.
Light Microscopy and Immunoelectron Microscopy of Retinas
Eyecups were processed for embedment in either LR White or Epon, and semithin and 
ultrathin sections were prepared. Semithin sections were stained with toluidine blue and 
visualised on a Leica confocal system. Ultrathin sections were labeled with purified 
MYO7A pAb 2.2 29 and monoclonal anti-opsin (1D4, R. Molday), followed by gold-
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conjugated secondary antibodies (Electron Microscopy Sciences, USA), as described 
previously 10. Negative control sections processed at the same time included those from 
Myo7a-null retinas, and, as positive control, WT animals were used.
MYO7A immunogold density was determined on sections of age-matched WT, Myo7a-null 
retinas and retinas of Myo7a-null animals that had been injected with AAV-MYO7A at 
P14-16 and dissected three weeks later. For quantification of the immunolabel all the gold 
particles in a complete section of each RPE cell were counted. The area of each cell’s profile 
was determined using ImageJ software. For background labeling, the concentration of label 
in sections of untreated Myo7a-null animals was measured. Data are expressed with this 
background labeling subtracted.
The concentration of MYO7A and opsin immunogold labeling in the connecting cilia of 
photoreceptor cells was determined by counting gold particles along longitudinal profiles of 
connecting cilia and measuring the length of each profile.
Analysis and quantifications were performed in a minimum of 3 different retinas, from three 
different animals. Statistical analysis was performed using one tail Student t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Expression of MYO7A from single AAV2 and AAV5 vectors in cultured cells. (a) Diagram 
of the viral vector encoding human MYO7A cDNA. (b) Western blot of WT eyecup (lane 1), 
primary RPE cultures derived from Myo7a-null mice and infected with AAV2-MYO7A (lane 
2) or AAV5-MYO7A (lane 3), or not infected (lane 4), and primary RPE cultures derived 
from Myo7a+/− mice (lane 5). All lanes were immunolabeled with antibodies against actin 
(as a loading indicator of relative protein loading) and MYO7A. (c-f) Immunofluorescence 
images of primary RPE cell cultures. Cells derived from Myo7a-null mice that were not 
infected (c), from Myo7a+/− mice (d), or from Myo7a-null mice infected with 1x AAV2-
MYO7A (e) or 1x AAV5-MYO7A (f). Scale = 10 μm.
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Fig. 2. 
Expression of MYO7A from single AAV2 and AAV5 vectors in vivo. (a-e) EM images of 
MYO7A immunogold labelling of the connecting cilium and pericilium from rod 
photoreceptors in a Myo7a-null retina. (a) Longitudinal section from an untreated Myo7a-
null retina (background label only). (b, c) Longitudinal sections from Myo7a-null retinas 
treated with 1x AAV2-MYO7A (b) or AAV5-MYO7A (c). Scale = 200 nm. (d, e) Transverse 
sections of connecting cilia from rod photoreceptors in Myo7a-null retinas treated with 1x 
AAV2-MYO7A (d) or AAV5-MYO7A (e). Scale = 100 nm. (f-g) EM images of RPE cells 
from Myo7a-null retinas treated with 1x AAV2-MYO7A (f) or AAV5-MYO7A (g). Scale = 2 
μm. BM = Bruch’s Membrane, AP = Apical Processes. Areas indicated by rectangles are 
enlarged in f’ and g’, in order to show MYO7A immunogold labeling (indicated by circles). 
Scale = 500 nm. (h, i) EM image of a longitudinal section of the connecting cilium and 
pericilium from a rod (h) and a cone (i) photoreceptor in a Myo7a-null retina, treated with 1x 
AAV2-MYO7A. The section was double-labeled with MYO7A (12 nm gold) and rod opsin 
(15 nm gold) antibodies. Rod outer segments were labeled with the opsin antibody, while 
cones were identified by lack of rod opsin labeling in their outer segments. The sections 
show just the base of the outer segments. Nearly all the label in the connecting cilium is 
MYO7A, even in the rod. Scale = 200 nm. (i-l) Bar graphs indicating MYO7A immunogold 
particle density in the rod photoreceptor cilium and pericilium (j, k) and in the RPE (l, m), 
following treatment with AAV2-MYO7A (j, l) or AAV5-MYO7A (k, m) of different 
concentrations. n=3 animals per condition. Bars indicate SEM.
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Fig. 3. 
Correction of mutant phenotypes, following subretinal injections with AAV2-MYO7A or 
AAV5-MYO7A. (a-e) Correction of melanosome localization. Light micrographs showing 
the presence of melanosomes in the apical processes of the RPE in a WT retina (a) and 
retinas injected with 1x AAV2-MYO7A (b) or AAV5-MYO7A (c). Further away from the 
injection site (d), melanosomes are present in the apical processes of some RPE cells, but 
not in others (arrows indicate apical melanosomes; white lines indicate regions where 
melanosomes are absent from the apical processes). (e) Region distant from injection site, 
where all RPE cells lack melanosomes in their apical processes. Brackets on left side 
indicate RPE apical processes. Scale = 8 μm. (f) Diagram of a dorso-ventral section through 
an eyecup, indicating the relative locations of the images shown in a-e. Arrow indicates the 
site of injection, ONH indicates the optic nerve head. (g) Correction of abnormal levels of 
opsin in the connecting cilium and pericilium of rod photoreceptors. Bar graph showing 
opsin immunogold gold particle density, along the length of the connecting cilium. Ultrathin 
sections of retinas from Myo7a-null and WT mice were stained with rod opsin antibody. The 
Myo7a-null retinas had been either not treated or treated with 1x or 1:100 AAV2-MYO7A or 
AAV5-MYO7A. N = 3 animals per condition. Bars indicate SEM.
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Fig. 4. 
Expression of MYO7A from the overlapping AAV2-MYO7A dual vectors. (a) Diagram of 
the the overlapping AAV2-MYO7A dual vectors. The overlapping region contains 1365 
bases. (b) Western blot of proteins from primary RPE cultures derived from Myo7a-null 
mice and not infected (lane 1), or infected with AAV2-MYO7A(dual) (lane 2); and primary 
RPE cultures derived from Myo7a+/− mice (lane 3). All lanes were immunolabeled with 
anti-MYO7A and anti-actin. (c) Western blot of primary cultures derived from Myo7a-null 
mice and not infected (lane 1), or infected with AAV2-MYO7A(dual (lane 2) or with AAV5-
MYO7A single vector (1x) (lane 3). Lanes were immunolabeled with anti-MYO7A and anti-
actin. Densitometry of the actin labeling showed that lane 2 was loaded with 3-fold more 
protein than lane 3; the MYO7A to actin ratio is 7-fold greater in lane 3 compared with lane 
2 in this blot. (d-g) Immunofluorescence of cultured RPE cells transduced with AAV2-
MYO7A(dual). (d-f) Primary RPE cultures derived from Myo7a-null mice and (g) ARPE19 
cells. Scale = 10 μm. (h) Bar graph indicating the distribution of MYO7A immunogold 
particle density among RPE cells from retinas of Myo7a-null mice, injected with AAV2-
MYO7A(dual). N = 3 animals.
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Fig. 5. 
Correction of mutant phenotypes, following subretinal injections with AAV2-MYO7A(dual). 
(a) Light microscopy of a semi-thin section from a treated Myo7a-null mouse retina. Region 
shown is near the injection site. Arrows indicate melanosomes in the apical processes. White 
lines indicate cells that still show the Myo7a-null phenotype, with an absence of 
melanosomes in the apical processes. Scale = 10 μm. (b) Low magnification of an 
immunoEM image of the RPE from a retina treated with AAV2-MYO7A(dual). As in a, the 
white line indicates a region that still shows the Myo7a-null phenotype. Rectangle, c, 
includes melanosomes in the apical region, indicating a corrected RPE cell. Scale = 10 μm. 
(c-e) Higher magnification of regions outlined by rectangles in b. MYO7A immunogold 
particles are indicated by circles. Scale = 1 μm. (f) Bar graph illustrating MYO7A 
immunogold particle density measured in RPE cells from Myo7a-null retinas, WT retinas, or 
from Myo7a-null retinas treated with AAV2-MYO7A(dual) and determined to be corrected 
or not corrected by the location of their apical melanosomes. N = 3 animals per condition. 
Bars indicate SEM. (g) ImmunoEM image of a rod photoreceptor cilium double-labeled 
with antibodies against MYO7A (small gold particles) and against rod opsin (large gold 
particles). MYO7A labeling is associated with the connecting cilium and periciliary 
membrane, indicating expression and correct localization of MYO7A, while this region is 
devoid of opsin labeling, which is restricted to the disk membranes, consistent with the WT 
phenotype, thus indicating correction of the mutant phenotype. Scale = 300 nm.
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